Milestone-Medtronic's Pipeline(TM) blood flow-guided dense mesh stent gains authoritative clinical verification again

Shanghai, September 30, 2021/PRNewswire/ - In September 2021, "Neurosurgery" magazine newly released the PEDESTRIAN1 study, which has had a huge impact on the entire neurointerventional academic community

Intracranial aneurysm (Intracranial aneurysm) is a tumor-like protrusion formed by the localized abnormal changes of cerebral arteries, and it is one of the most common cerebrovascular diseases

The clinical treatment of aneurysms is mainly surgery, and the specific plans mainly include: endovascular embolization of the aneurysm and craniotomy to clamp the aneurysm2

With the passage of time, the endovascular treatment technology for intracranial aneurysms has been continuously upgraded

PipelineTM blood flow guided dense mesh stent can repair the diseased blood vessel segment where the intracranial aneurysm is located and reconstruct the local artery.

Traditional endovascular coil embolization treatment strategies have certain limitations, because the ultimate goal of treating aneurysms is to permanently occlude the aneurysm, which requires sealing the aneurysm neck and blocking the passage of blood into the aneurysm.

The continuous improvement of the blood flow-directed dense mesh stent and the undisputed clinical results have made clinicians widely recognized the clinical value of this technology3

In the Chinese market, in 2017, the second-generation technology PipelineTMFlex blood flow-oriented dense network stent technology obtained China CFDA (now renamed China NMPA) certification, and the technology officially began to serve a large number of patients in China

The large sample size and high-quality clinical research of the PipelineTM blood flow-oriented dense mesh stent technology is also constantly developing.

*Remark:

1.

2.

In the past ten years, tens of thousands of patients at home and abroad have received the treatment of this technology and benefited from the advanced medical technology.

references:

1.

2.

3.

4.

5.
Hanel RA, Kallmes DF, etc.
Prospective study on embolization of intracranial aneurysms with the pipeline device: the PREMIER study 1 year results.
J Neurointerv Surg.
2020 Jan;12(1):62-66.
doi: 10.
1136/neurintsurg -2019-015091.
Epub 2019 Jul 15.
PMID: 31308197; PMCID: PMC6996098.

6.
Becske T, Brinjikji W, etc.
Long-Term Clinical and Angiographic Outcomes Following Pipeline Embolization Device Treatment of Complex Internal Carotid Artery Aneurysms: Five-Year Results of the Pipeline for Uncoilable or Failed Aneurysms Trial.
Neurosurgery.
2017 Jan 1;80 (1):40-48.
doi: 10.
1093/neuros/nyw014.
PMID: 28362885.

7.
Kallmes DF, Brinjikji W, etc.
Aneurysm Study of Pipeline in an Observational Registry (ASPIRe).
Interv Neurol.
2016 Jun;5(1-2):89-99.
doi: 10.
1159/000446503.
Epub 2016 May 26.
PMID: 27610126; PMCID: PMC4934472.

8.
Kallmes DF, Hanel R, etc.
International retrospective study of the pipeline embolization device: a multicenter aneurysm treatment study.
AJNR Am J Neuroradiol.
2015 Jan;36(1):108-15.
doi: 10.
3174/ajnr.
A4111.
Epub 2014 Oct 29.
Erratum in: AJNR Am J Neuroradiol.
2015 May;36(5):E39-40.
PMID: 25355814; PMCID: PMC7965920.

9.
Luo B, Kang H, etc.
Pipeline Embolization device for intracranial aneurysms in a large Chinese cohort: factors related to aneurysm occlusion.
Ther Adv Neurol Disord.
2020 Nov 2;13:1756286420967828.
doi: 10.
1177/1756286420967828.
PMID: 33224273 ; PMCID: PMC7649855.

*This article aims to convey cutting-edge medical information and research progress, and is only for educational or popular science purposes, and should not be regarded as a recommendation or proof of efficacy for the medical products involved
.
Involved in disease diagnosis, treatment, and rehabilitation, please be sure to go to a professional medical institution to seek professional advice
.

Source: Medtronic